Martiniano Stacey L, Nick Jerry A, Daley Charles L
Department of Pediatrics, Children's Hospital Colorado, University of Colorado Denver School of Medicine, 13123 East 16th Avenue, Box B-395, Aurora, CO 80045, USA.
Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA; Department of Medicine, University of Colorado Anschutz Medical Campus, 13001 E. 17th Place, Aurora, CO 80045, USA.
Thorac Surg Clin. 2019 Feb;29(1):95-108. doi: 10.1016/j.thorsurg.2018.09.008.
Nontuberculous mycobacteria (NTM) are important emerging cystic fibrosis (CF) pathogens, with estimates of prevalence ranging from 6% to 13%. Diagnosis of NTM disease in patients with CF is challenging, as the infection may remain indolent in some, without evidence of clinical consequence, whereas other patients suffer significant morbidity and mortality. Treatment requires prolonged periods of multiple drugs and varies depending on NTM species, resistance pattern, and extent of disease. The development of a disease-specific approach to the diagnosis and treatment of NTM infection in CF patients is a research priority, as a lifelong strategy is needed for this high-risk population.
非结核分枝杆菌(NTM)是重要的、新出现的囊性纤维化(CF)病原体,据估计其患病率在6%至13%之间。CF患者的NTM病诊断具有挑战性,因为在一些患者中感染可能进展缓慢,没有临床后果的证据,而其他患者则会出现严重的发病和死亡情况。治疗需要长期使用多种药物,且因NTM菌种、耐药模式和疾病程度而异。针对CF患者NTM感染的诊断和治疗制定一种疾病特异性方法是一项研究重点,因为对于这一高风险人群需要一种终身策略。